BigHat Biosciences
CA - San MateoBiotechnology
Focus: BigHat Biosciences is a Series B biotechnology company leveraging machine learning and synthetic biology to design safer, more effective biologic therapies. The company is early-stage with a single program in Phase 1/2 for gastric cancer.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
15
Should You Work at BigHat Biosciences?
AI assessmentBest suited for scientists and technologists comfortable with pre-clinical risk seeking hands-on impact at a capital-efficient, AI-enabled biotech.
Why Work Here
- Join a founding-stage team with cutting-edge AI/ML-driven drug discovery platform that just dosed the first patient with BHB810 in September 2026
- Heavy hiring in Lab Science (9 roles) and IT (3 roles) indicates active platform development and infrastructure scaling
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BHB810
Gastric CancerClinical Trials (1)
NCT07529808Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Phase 1/2Help build intelligence for BigHat Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.